EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Calcitriol Treatment Is Safe and Increases Frataxin Levels in Friedreich Ataxia Patients

Berta Alemany-Perna iD, Jordi Tamarit, Elisa Cabiscol, Fabien Delaspre, Albert Miguela, Joana Maria Huertas-Pons, Ana Quiroga-Varela, Miguel Merchan Ruiz, Daniel López Domínguez, Lluís Ramió I Torrentà, David Genís, Joaquim Ros

Movement Disorders · 2024-07 · 39 (7) · 1099-1108

DOI: 10.1002/mds.29808 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders, online erschienen am 02.05.2024. Verfasst von Berta Alemany-Perna und 11 weiteren Autor:innen. Beteiligte Einrichtung: Ataxia Unit, Neurology Service, ICS/IAS, Hospital Josep Trueta/Hospital Santa Caterina, Girona/Salt, Spain. Hauptthemen laut MEDLINE: Friedreich Ataxia, Frataxin, Calcitriol, Iron-Binding Proteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Federacion Española de Ataxias (FEDAES), Ministerio de Ciencia e Innovación (Spain), Open Access funding provided thanks to the CRUE-CSIC agreement with Wiley and the University of Girona (UdG).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Calcitriol, the active form of vitamin D (also known as 1,25‐dihydroxycholecalciferol), improves the phenotype and increases frataxin levels in cell models of Friedreich ataxia (FRDA).

Objectives

Based on these results, we aimed measuring the effects of a calcitriol dose of 0.25 mcg/24h in the neurological function and frataxin levels when administered to FRDA patients for a year.

Methods

20 FRDA patients where recluted and 15 patients completed the treatment for a year. Evaluations of neurological function changes (SARA scale, 9‐HPT, 8‐MWT, PATA test) and quality of life (Barthel Scale and Short Form (36) Health Survey [SF‐36] quality of life questionnaire) were performed. Frataxin amounts were measured in isolated platelets obtained from these FRDA patients, from heterozygous FRDA carriers (relatives of the FA patients) and from non‐heterozygous sex and age matched controls.

Results

Although the patients did not experience any observable neurological improvement, there was a statistically significant increase in frataxin levels from initial values, 5.5 to 7.0 pg/μg after 12 months. Differences in frataxin levels referred to total protein levels were observed among sex‐ and age‐matched controls (18.1 pg/μg), relative controls (10.1 pg/μg), and FRDA patients (5.7 pg/μg). The treatment was well tolerated by most patients, and only some of them experienced minor adverse effects at the beginning of the trial.

Conclusions

Calcitriol dosage used (0.25 mcg/24 h) is safe for FRDA patients, and it increases frataxin levels. We cannot rule out that higher doses administered longer could yield neurological benefits. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Friedreich AtaxiaFrataxinCalcitriolIron-Binding ProteinsHumansMaleFemaleAdultMiddle AgedYoung AdultQuality of LifeAdolescentTreatment Outcome

Stichwörter der Autor:innen

Friedreich ataxiaataxiacalcitriolfrataxinvitamin D

Substanzen

FrataxinCalcitriolIron-Binding Proteins

Autor:innen und Institutionen

  • Ataxia Unit, Neurology Service, ICS/IAS, Hospital Josep Trueta/Hospital Santa Caterina, Girona/Salt, Spain.
  • Department of Medical Sciences, University of Girona (UdG), Girona, Spain.
  • Neurodegeneration and Neuroinflammacion Group, Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spain.
  • Departament de Ciències Mèdiques Bàsiques, Institut de Recerca Biomèdica de Lleida (IRBLleida), Universitat de Lleida, Lleida, Spain.
  • Neurology Service, ICS/IAS, Hospital Josep Trueta/Hospital Santa Caterina, Girona/Salt, Neurodegeneration and Neuroinflammacion Group (IDIBGI), Girona/Salt, Spain.

ORCID-Profile: Berta Alemany-Perna

Förderung

  • Federacion Española de Ataxias (FEDAES)
  • Ministerio de Ciencia e Innovación (Spain)
  • Open Access funding provided thanks to the CRUE-CSIC agreement with Wiley and the University of Girona (UdG)

Zitieren

APA

Alemany-Perna, B., Tamarit, J., Cabiscol, E., Delaspre, F., Miguela, A., Huertas-Pons, J. M., Quiroga-Varela, A., Merchan Ruiz, M., López Domínguez, D., Ramió I Torrentà, L., Genís, D., & Ros, J. (2024). Calcitriol Treatment Is Safe and Increases Frataxin Levels in Friedreich Ataxia Patients. Movement Disorders, 39(7), 1099-1108. https://doi.org/10.1002/mds.29808

Vancouver

Alemany-Perna B, Tamarit J, Cabiscol E, Delaspre F, Miguela A, Huertas-Pons JM, et al. Calcitriol Treatment Is Safe and Increases Frataxin Levels in Friedreich Ataxia Patients. Movement Disorders. 2024;39(7):1099-1108. doi:10.1002/mds.29808

BibTeX
@article{AlemanyPerna2024,
  author = {Alemany-Perna, Berta and Tamarit, Jordi and Cabiscol, Elisa and Delaspre, Fabien and Miguela, Albert and Huertas-Pons, Joana Maria and Quiroga-Varela, Ana and Merchan Ruiz, Miguel and López Domínguez, Daniel and Ramió I Torrentà, Lluís and Genís, David and Ros, Joaquim},
  title = {Calcitriol Treatment Is Safe and Increases Frataxin Levels in Friedreich Ataxia Patients},
  journal = {Movement Disorders},
  year = {2024},
  volume = {39},
  number = {7},
  pages = {1099--1108},
  doi = {10.1002/mds.29808}
}
Kostenlos starten →